A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
MRI Criteria for MS in Patients with Clinically Isolated Syndromes
Neurol 74:427-434, Montalban,X.,et al, 2010
Childhood Posterior Circulation Arterial Ischemic Stroke
Stroke 41:2201-2209, Mackay,M.T.,et al, 2010
Neuromyelitis Optica Treatment: Analysis of 36 Patients
Arch Neurol 67:1131-1136, Bichuetti,D.B.,et al, 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Multifocal Strokes as the Initial Manifestation of Metastatic Tumors
Neurologist 16:322-324, Park,H.-Y.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Anti-NMDA Receptor Encephalitis Causing Prolonged Nonconvulsive Status Epilepticus
Neurol 75:1480-1482, Johnson,N.,et al, 2010
Non-Paraneoplastic Limbic Encephalitis Characterized by Mesio-Temporal Seizures and Extratemporal Lesions: A Case Report
Seizure 19:446-449, Cianci,V.,et al, 2010
Diagnostic Role of Target Lesion on Diffusion-WEighted Imaging, A Case of Cerebral Aspergillosis and Review of the Literature
Neurologist 16:364-367, Finelli,P.F.,et al, 2010
Critical Vasospasm During Fingolimod (FTY720) Treatment in a Patient With Multiple Sclerosis
Neurol 74:2022-2024, Schwarz,A., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Delirious Deficiency
Lancet 376:1362, Olsen,R.Q &Regis,J.T., 2010
Cerebral Infarcts in the Setting of Eosinophilia
Arch Neurol 67:1275-1277, Sethi,H.S. &Schmidley,J.W., 2010
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
Rapid Disease Course in African Americans With Multiple Sclerosis
Neurol 75:217-223, Kister,I., et al, 2010
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types
AJNR 31:541-548, 390, Vrenken,H.,et al, 2010
Sjogren Syndrome: Neurologic Complications
www.Medlink.com,Jan, Roman,G.C., 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Perioperative Visual Loss in Ocular and Nonocular Surgery
Clin Ophthalmol 4:531-546, Berg, K.T.,et al, 2010
Spinal Cord Involvement in Balos Concentric Sclerosis
J Neurol Sci 279:114-117, Kreft, K.L.,et al, 2009
"Cloud-like Enhancement" Is a Magnetic Resonance Imaging Abnormality Specific to Neuromyelitis Optica
Ann Neuro l 66:425-428, Ito, S.,et al, 2009
Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009
Multiple Bilateral Non-Hemorrhagic Cerebral Infarctions Associated with Microscopic Polyangiitis
Clin Neurol Neurosurg 111:904-906, Ku, B. & Shin, H., 2009
Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
JAMA 302:2565-2572, 2593, Lieb,W.,et al, 2009
Functional and Cognitive Outcome in Prolonged Refractory Status Epilepticus
Arch Neurol 66:1505-1509, Cooper,A.,et al, 2009
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil
Arch Neurol 66:1128-1133, Jacob,A.,et al, 2009
Multiple Sclerosis with Predominant, Severe Cognitive Impairment
Arch Neurol 66:1139-1143, Staff,N.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009
Seizure Relapse and Development of Drug Resistance Following Long-Term Seizure Remission
Arch Neurol 66:1233-1239, Schiller,Y., 2009
A 52-Year-Old Woman With Disabling Peripheral Neuropathy: Review of Diabetic Polyneuropathy
JAMA 302:1451-1458, Rutkove,S., 2009
Exclusive Breastfeeding and the Risk of Postpartum Relapses in Women with Multiple Sclerosis
Arch Neurol 66:958-963, Langer-Gould,A.,et al, 2009
Smoking Is Associated with Increased Lesion Volumes and Brain Atrophy in Multiple Sclerosis
Neurol 73:504-510, Zivadinov,R.,et al, 2009
Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009
Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009